Evidence map›Paper›PMID 27251218›Full record

ArticleMolecular biology reports2016

Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis.

Abdollah Kebriaei, Mohammad Derakhshan, Zahra Meshkat, Mohammad Reza Akbari Eidgahi, Seyed Abdolrahim Rezaee, Hadi Farsiani, Arman Mosavat, Saman Soleimanpour, Kiarash Ghazvini

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Immunogenicity of heparin-binding hemagglutinin expressed byIranian journal of basic medical sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Abdollah KebriaeiAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad DerakhshanAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra MeshkatAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza Akbari EidgahiBiotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Seyed Abdolrahim RezaeeInflammation and Inflammatory Diseases Research Centre, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran.
Hadi FarsianiAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Arman MosavatAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Saman SoleimanpourAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Kiarash GhazviniAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. ghazvinik@mums.ac.ir.
Mashhad University of Medical Sciences · IRSemnan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an ancient disease, tuberculosis (TB) is a major global health threat. Therefore, there is an urgent need for an effective and safe anti-TB vaccine. In the current study, a delivery system of Fc domain of mouse IgG2a and early secreted antigenic target protein 6 (ESAT-6) was evaluated for the selective uptake of antigens by antigen-presenting cells (APCs). Thus, it was based on the immunogenicity of a fusion protein. The study was initiated by the transfer of recombinant expression vectors of pPICZαA-ESAT-6:Fcγ2a and pPICZαA-ESAT-6: His into Pichia pastoris (P. pastoris). Recombinant proteins were assessed for immunogenicity following the immunoblotting analysis. High levels of IFN-γ and IL-12 were produced to induce Th1-type cellular responses through vaccination with both recombinant proteins [ESAT-6:Fcγ2a (EF) and ESAT-6:His (EH)]. The Fc-tagged recombinant protein induced more effective Th1-type cellular responses with a low increment in IL-4 compared to PBS, BCG, and EH groups. Although in all the immunized groups, the ratio of IFN-γ/IL-4 was in favor of Th1 responses, the highest Th1/Th2 balance was observed in EF immunized group. Fc fragment of mouse IgG2a may induce a selective uptake of APCs towards the cross-presentation and formation of Th1 responses in favor of an appropriate protective anti-tuberculosis reaction. Thus, further research on Fc-fusion proteins is required to develop Fc-based TB vaccines.

Indexed as

AnimalsAntigens, BacterialBacterial ProteinsFemaleImmunity, CellularImmunoglobulin Fc FragmentsInterferon-gammaInterleukin-12Interleukin-4Mice, Inbred C57BLMycobacterium tuberculosisPichiaRecombinant Fusion ProteinsTuberculosis, PulmonaryTuberculosis VaccinesVaccinationAntigens, BacterialBacterial ProteinsESAT-6 protein, Mycobacterium tuberculosisImmunoglobulin Fc FragmentsInterferon-gammaInterleukin-12Interleukin-4Recombinant Fusion ProteinsTuberculosis VaccinesVaccines, SubunitESAT-6Fc domainImmunogenicityMycobacterium tuberculosisSubunit vaccineTuberculosis

Identifiers

PMID27251218
OpenAlexW2410101441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.